Sarepta Therapeutics
SRPT
149 hedge funds and large institutions have $891M invested in Sarepta Therapeutics in 2015 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 43 reducing their positions, and 11 closing their positions.
173% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 11
73% more call options, than puts
Call options by funds: $94.2M | Put options by funds: $54.3M
33% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 43
15% more funds holding
Funds holding: 130 → 149 (+19)
10% more capital invested
Capital invested by funds: $811M → $891M (+$80.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$27.3M |
| 2 |
D.E. Shaw & Co
New York
|
+$18.5M |
| 3 |
Millennium Management
New York
|
+$17.2M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$15.9M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$47.5M |
| 2 |
HM
HealthCor Management
New York
|
-$11.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.94M |
| 4 |
Jennison Associates
New York
|
-$6.93M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.71M |
SRPT Hedge Fund Activity: Q3 2015 in Review
149 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2015, worth a combined $891M — up 9.9% from $811M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SRPT positions and 11 closed out — a net gain of 19 holders — while 57 added to existing stakes and 43 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $27.3M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $47.5M.
- 149 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2015, up from 130 in Q2 2015.
- Funds reported $891M of Sarepta Therapeutics stock for Q3 2015, up 9.9% quarter-over-quarter.
- 30 funds opened new Sarepta Therapeutics positions in Q3 2015 and 11 closed out, a net change of +19 holders.
- The largest Sarepta Therapeutics buyer in Q3 2015 was Citadel Advisors, an estimated $27.3M added.
- The largest Sarepta Therapeutics seller in Q3 2015 was Columbia Wanger Asset Management, an estimated $47.5M sold.
Based on aggregated 13F filings for Q3 2015.